Tagged with OBI

Italy Speaking recently to PharmaBoardoom, Assobiotec’s Leonardo Vingiani introduced the key dynamics shaping the Italian biotech industry today and the issues it still has to overcome to become truly globally competitive.   Strong Fundamentals The association’s latest reporting shows that there are 751 active biotech firms in Italy, with a turnover…

Italy Assobiotec’s Leonardo Vingiani introduces the key trends shaping the Italian biotech ecosystem today, the steps that the country’s government have taken to foster life sciences innovation, and the areas in which Italian biotechs truly excel globally.   Italy and its researchers have created a good environment for science. However, the…

China The latest from Chinese pharma, including a setback for CanSinoBIO’s Canadian COVID-19 vaccine trial, Bayer’s new Beijing manufacturing plant, and biotech Antengene’s potential USD 200 million IPO in Hong Kong.   Canada scraps COVID-19 vaccine trial with Chinese CanSinoBIO https://globalnews.ca/news/7302041/canada-china-covid-19-vaccine-trials-abandoned-national-research-council/ Canada has decided to cancel a coronavirus vaccine development agreement…

China Chinese biotech CanSinoBIO is racing against the clock to have a COVID-19 vaccine ready to begin production in early 2021. The firm’s senior VP of International Business Pierre Morgon reflects on CanSinoBIO’s progress thus far and a timeline of what we can realistically expect if and when Chinese authorities give…

Korea Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO, sat down with PharmaBoardroom to shed light on the company’s origins, its collaboration with Big Pharma, and the ease of gaining capital investment for a…

China Pierre A Morgon, SVP International Business for CanSino Biotechnology (CanSinoBIO) – a Chinese vaccine biotech developing one of the frontrunner COVID-19 vaccine candidates – shares how his extensive international career brought him to CanSinoBIO, the deeply-rooted public health orientation of the vaccines sector, the complex realities of developing and deploying…

China Mike Chen, president and CEO of ACROBiosystems, shares his global success as a manufacturer of recombinant proteins supporting biologics R&D and how he hopes to expand his business to eventually set up a multifaceted platform for MNCs and biotechs.   By having a manufacturing facility in the USA or Europe,…

Taiwan While Taiwanese pharmaceutical and biotech players have traditionally set their sights on the US as a key market, rising medical needs in Asia are helping foster more regionally-focused strategies.   According to data from the World Bank, healthcare spending in Asia is expected to grow at a CAGR of 9.2…

China Dr. Zhengyu Yuan, president & CEO of MicuRx, shares the story of how MicuRx was founded in 2007 to develop new and innovative antimicrobial drugs; their flagship product, contezolid, which recently concluded Phase III trials in China; and their future plans for an IPO.   We combined US experience and…

Sweden Having more than 20 years’ experience in the beverage industry, Isabelle Ducellier was appointed as the CEO of Swedish probiotics company BioGaia in November 2018. Here, Ducellier highlights her goal of moving the company into the B2B/B2C sector, regulatory obstacles for clinically proven probiotics and BioGaia’s long term strategy.  …

Sweden Elisabeth Svanberg MD, PhD, a seasoned industry expert, having worked for established MNCs such as Serono, BMS & J&J, now sits on the board of Sweden’s national champion SOBI, is a Swede at heart and shares her views on the strengths of Sweden’s healthcare and life sciences ecosystem. Svanberg stresses…

Taiwan Dr Michael Chang, founder and chairman of OBI Pharma, shares the history of his company’s beginnings and highlights the current progress of its innovative immune-oncology pipeline. Dr Chang goes on to comment on the condition of the Asian market while explaining his vision for OBI as a biotech role model…